Literature DB >> 16028013

Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae.

Karunya K Kandimalla1, Maureen D Donovan.   

Abstract

PURPOSE: The purpose of this study was to demonstrate that P-glycoprotein (P-gp) is localized in the olfactory mucosa and is capable of limiting the nose-to-brain transport of substrates. Bovine olfactory and nasal respiratory mucosae were compared to both localize P-gp and to measure its activity within the epithelia.
METHODS: Immunolocalization was performed on the bovine olfactory and nasal respiratory mucosa using the C219 monoclonal antibody. Flux of etoposide, a substrate reported to be primarily effluxed by P-gp, across bovine olfactory and nasal respiratory mucosae was measured using Sweetana-Grass (Navicyte) vertical diffusion cells. Experiments were performed to evaluate the effect of directionality, donor concentration, and the presence of inhibitors.
RESULTS: Dense staining was observed on the apical surface of the ciliated epithelial cells and within the submucosal lymphatics/vasculature and mucosal glands of the bovine olfactory and nasal respiratory mucosae. Staining in the nasal respiratory epithelium was weak and patchy when compared to that observed in the olfactory mucosa. The secretory transport (Js-m) kinetics of etoposide in the olfactory (Km = 260.5 microM, Vmax = 0.179 microM/cm(2) min) and nasal respiratory (Km = 46.9 microM, Vmax = 0.034 microM/cm(2) min) mucosae were observed to be saturable and concentration-dependent. The flux of etoposide in the submucosal-mucosal (Js-m) direction was significantly greater than the flux in the mucosal-submucosal (Jm-s) direction in both the olfactory and nasal respiratory mucosa. The efflux ratios (Js-m/Jm-s) of etoposide across the olfactory and the nasal respiratory mucosae were 2.02 and 2.10, respectively. In the presence of inhibitors such as 2,4-dinitrophenol (1 mM) and quinidine (1 mM), etoposide showed an increase in Jm-s and a decrease in Js-m. The etoposide efflux was unaffected in the presence of a specific multiresistance associated protein 1 (MRP1) inhibitor (MK571) and methotrexate, a substrate for BCRP and MRP1-4.
CONCLUSIONS: P-gp was localized in the epithelial cells, nasal glands, and the vascular endothelium of both the bovine olfactory and nasal respiratory mucosae, and the expressed P-gp was capable of effluxing a substrate such as etoposide. The Km and Vmax of etoposide efflux were higher in the olfactory mucosa compared to the nasal respiratory mucosa, and the expression of P-gp seems to be greater in the olfactory epithelium compared to the nasal respiratory epithelium based on the staining density observed using immunohistochemistry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16028013     DOI: 10.1007/s11095-005-5420-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  44 in total

1.  Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium.

Authors:  M C Schmidt; D Simmen; M Hilbe; P Boderke; G Ditzinger; J Sandow; S Lang; W Rubas; H P Merkle
Journal:  J Pharm Sci       Date:  2000-03       Impact factor: 3.534

2.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  J Histochem Cytochem       Date:  1989-02       Impact factor: 2.479

3.  Functional evidence for P-glycoprotein at the nose-brain barrier.

Authors:  Candace L Graff; Gary M Pollack
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

Review 4.  Alterations in epithelial polarity and the pathogenesis of disease states.

Authors:  E M Fish; B A Molitoris
Journal:  N Engl J Med       Date:  1994-06-02       Impact factor: 91.245

5.  Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats.

Authors:  H S Chow; Z Chen; G T Matsuura
Journal:  J Pharm Sci       Date:  1999-08       Impact factor: 3.534

6.  Multidrug resistance-associated protein-1 functional activity in Calu-3 cells.

Authors:  K O Hamilton; E Topp; I Makagiansar; T Siahaan; M Yazdanian; K L Audus
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

7.  Active efflux kinetics of etoposide from rabbit small intestine and colon.

Authors:  J Kunta; J Yan; V D Makhey; P J Sinko
Journal:  Biopharm Drug Dispos       Date:  2000-04       Impact factor: 1.627

8.  Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.

Authors:  V D Makhey; A Guo; D A Norris; P Hu; J Yan; P J Sinko
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

9.  A pharmacokinetic study of midazolam in dogs: nasal drop vs. atomizer administration.

Authors:  R J Henry; N Ruano; D Casto; R H Wolf
Journal:  Pediatr Dent       Date:  1998 Sep-Oct       Impact factor: 1.874

Review 10.  Fine structure of the vomeronasal and septal olfactory epithelia and of glandular structures.

Authors:  D R Adams
Journal:  Microsc Res Tech       Date:  1992-10-01       Impact factor: 2.769

View more
  10 in total

1.  Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?

Authors:  Janet Hardy; Ross Norris; Helen Anderson; Angela O'Shea; Bruce Charles
Journal:  Support Care Cancer       Date:  2011-04-15       Impact factor: 3.603

2.  Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats.

Authors:  M Ludwig; V A Tobin; M F Callahan; E Papadaki; A Becker; M Engelmann; G Leng
Journal:  J Neuroendocrinol       Date:  2013-07       Impact factor: 3.627

3.  Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution.

Authors:  John Douglas Hoekman; Rodney J Y Ho
Journal:  AAPS PharmSciTech       Date:  2011-04-26       Impact factor: 3.246

4.  Microarray Determination of the Expression of Drug Transporters in Humans and Animal Species Used for the Investigation of Nasal Absorption.

Authors:  Manar Al-Ghabeish; Todd Scheetz; Mahfoud Assem; Maureen D Donovan
Journal:  Mol Pharm       Date:  2015-07-10       Impact factor: 4.939

5.  Demonstration of Nucleoside Transporter Activity in the Nose-to-Brain Distribution of [18F]Fluorothymidine Using PET Imaging.

Authors:  Laura L Boles Ponto; Jiangeng Huang; Susan A Walsh; Michael R Acevedo; Christine Mundt; John Sunderland; Maureen Donovan
Journal:  AAPS J       Date:  2017-12-07       Impact factor: 4.009

6.  Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20).

Authors:  Gloriane W Schnabolk; Geri L Youngblood; Douglas H Sweet
Journal:  Am J Physiol Renal Physiol       Date:  2006-02-14

Review 7.  Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.

Authors:  Leah R Hanson; William H Frey
Journal:  J Neuroimmune Pharmacol       Date:  2006-09-15       Impact factor: 4.147

8.  Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs.

Authors:  Hiroko Enomoto; Lydia Love; Melanie Madsen; Amber Wallace; Kristen M Messenger
Journal:  J Vet Pharmacol Ther       Date:  2022-04-21       Impact factor: 1.567

9.  Functional evidence of multidrug resistance transporters (MDR) in rodent olfactory epithelium.

Authors:  Adrien Molinas; Gilles Sicard; Ingrid Jakob
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

10.  A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs.

Authors:  Jasper Stevens; Ernst Suidgeest; Piet Hein van der Graaf; Meindert Danhof; Elizabeth C M de Lange
Journal:  Pharm Res       Date:  2009-05-19       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.